Post Content
Wave Life Sciences Ltd. (NASDAQ:WVE) is one of the
8 Healthcare Stocks Insiders Are Buying. On April 7, 2026, RBC Capital analyst Luca Issi lowered the price target on Wave Life Sciences Ltd. (NASDAQ:WVE) to $15 from $27 and maintained an Outperform rating as part of a Q1 biotech preview. Luca Issi said seasonal headwinds around gross-to-net, reimbursement resets, and fewer selling days may be exacerbated by weather impacts, particularly for launching and in-clinic products, while noting that a return of M&A activity and clarity on tariff and Most Favored Nation drug pricing could help offset broader macro pressures.
On March 27, 2026, BofA lowered its price target on Wave Life Sciences to $21 from $38 and maintained a Buy rating following updated Phase 1 data for WVE-007 in obesity. BofA said additional data is needed to support the monotherapy case, but noted potential opportunities in higher BMI patients and in combination or maintenance settings.
Copyright: nexusplexus / 123RF Stock Photo
On March 26, 2026, Wave Life Sciences reported new Phase 1 INLIGHT trial data for WVE-007, showing that a single 240 mg dose led to reductions in visceral fat, waist circumference, and body weight, while preserving muscle, with up to 88% reduction in Activin E sustained for at least seven months. The treatment was generally safe and well-tolerated, with no serious adverse events, and additional cohorts showed similar trends, supporting plans to begin a Phase 2a multidose study in the second quarter of 2026 and further trials evaluating monotherapy and combination approaches.
Wave Life Sciences Ltd. (NASDAQ:WVE) develops RNA-based therapeutics.
While we acknowledge the potential of WVE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.